University of Chicago Medical Center-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2022

  1. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

    Blood, Vol. 139, Núm. 4, pp. 492-501

2020

  1. First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 26, Núm. 10, pp. 2308-2317

2019

  1. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

    Blood, Vol. 134, Núm. 5, pp. 421-431

2017

  1. Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM)

    Annals of Translational Medicine, Vol. 5, Núm. 19

2011

  1. Defining the critical hurdles in cancer immunotherapy

    Journal of Translational Medicine